Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Update

Key Points

• Entera Bio Ltd. saw a significant reduction in short interest, dropping by 33.0% in August from the previous month, bringing the total to 37,200 shares.
• The company's stock declined 4.6% to $2.06, with a market capitalization of approximately $94.06 million and a consensus rating of "Strong Buy" from analysts.
• Institutional investors have increased their stake in Entera Bio, with notable increases from Northern Trust Corp and Knoll Capital Management, highlighting growing institutional interest.

Entera Bio Ltd. (NASDAQ:ENTX - Get Free Report) was the target of a large decrease in short interest in the month of August. As of August 15th, there was short interest totaling 37,200 shares, a decrease of 33.0% from the July 31st total of 55,500 shares. Based on an average trading volume of 118,100 shares, the short-interest ratio is presently 0.3 days. Based on an average trading volume of 118,100 shares, the short-interest ratio is presently 0.3 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright upgraded Entera Bio to a "strong-buy" rating in a report on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating, According to MarketBeat.com, Entera Bio presently has an average rating of "Strong Buy" and a consensus target price of $10.00.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Bessemer Group Inc. purchased a new position in shares of Entera Bio during the 2nd quarter worth $268,000. Parkman Healthcare Partners LLC lifted its stake in shares of Entera Bio by 6.3% during the 1st quarter. Parkman Healthcare Partners LLC now owns 439,632 shares of the company's stock worth $747,000 after purchasing an additional 25,900 shares during the period. HighTower Advisors LLC lifted its stake in shares of Entera Bio by 53.3% during the 1st quarter. HighTower Advisors LLC now owns 18,140 shares of the company's stock worth $31,000 after purchasing an additional 6,310 shares during the period. Knoll Capital Management LLC lifted its stake in shares of Entera Bio by 51.5% during the 4th quarter. Knoll Capital Management LLC now owns 5,881,879 shares of the company's stock worth $12,470,000 after purchasing an additional 2,000,000 shares during the period. Finally, Northern Trust Corp purchased a new position in shares of Entera Bio during the 4th quarter worth $450,000. Hedge funds and other institutional investors own 14.11% of the company's stock.

Entera Bio Price Performance

NASDAQ:ENTX traded down $0.05 during trading hours on Friday, reaching $1.80. 100,965 shares of the company traded hands, compared to its average volume of 100,624. The firm's 50-day moving average is $1.94 and its 200-day moving average is $1.94. The stock has a market cap of $82.19 million, a P/E ratio of -6.92 and a beta of 1.69. Entera Bio has a 1-year low of $1.50 and a 1-year high of $2.79.

Entera Bio (NASDAQ:ENTX - Get Free Report) last announced its earnings results on Friday, August 8th. The company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.05. Entera Bio had a negative return on equity of 77.75% and a negative net margin of 4,525.11%. As a group, research analysts predict that Entera Bio will post -0.28 earnings per share for the current year.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.